Anti-ASGR1 neutralizing antibodies in mice show synergistic effects on serum cholesterol relative to some currently used lipid modifiers (i.e. statins and ezetimibe) [4], highlighting ASGR1 as a possible therapeutic target for lowering cholesterol and preventing cardiovascular diseases (CVD) [5]. The gene discussed is ASGR1; the disease is cardiovascular disorder.